Cargando…
Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models
INTRODUCTION: Numerous intrinsic and extrinsic factors have been associated with the pathophysiology of rosacea, including dysregulation of innate immunity. A high level of cathelicidin antimicrobial peptides (e.g., LL-37) has been shown in the facial skin of patients with rosacea. Excessive product...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453918/ https://www.ncbi.nlm.nih.gov/pubmed/28243927 http://dx.doi.org/10.1007/s13555-017-0176-3 |
_version_ | 1783240735162630144 |
---|---|
author | Thibaut de Ménonville, Séverine Rosignoli, Carine Soares, Estelle Roquet, Manon Bertino, Béatrice Chappuis, Jean-Paul Defoin-Platel/Chaussade, Claire Piwnica, David |
author_facet | Thibaut de Ménonville, Séverine Rosignoli, Carine Soares, Estelle Roquet, Manon Bertino, Béatrice Chappuis, Jean-Paul Defoin-Platel/Chaussade, Claire Piwnica, David |
author_sort | Thibaut de Ménonville, Séverine |
collection | PubMed |
description | INTRODUCTION: Numerous intrinsic and extrinsic factors have been associated with the pathophysiology of rosacea, including dysregulation of innate immunity. A high level of cathelicidin antimicrobial peptides (e.g., LL-37) has been shown in the facial skin of patients with rosacea. Excessive production of both LL-37 and KLK5, the serine protease responsible for its cleavage, has been suggested to play a role in the pathophysiology of rosacea. Ivermectin 10 mg/g cream, indicated for the treatment of inflammatory lesions of rosacea, is reported to have dual anti-parasitic and anti-inflammatory properties. However, the exact mechanism of action of ivermectin cream in the treatment of rosacea is unknown. METHODS: This study aimed to evaluate the effect of ivermectin on the expression of KLK5 and the subsequent effect on the maturation process of cathelicidins. Experimental studies were performed either on normal human epidermal keratinocytes (NHEK), reconstructed human epidermis (RHE) or on human skin ex vivo stimulated with calcitriol (1α,25-dihydroxyvitamin D3), which is known to induce KLK5 and LL-37 expression. RESULTS: The results show that ivermectin is able to inhibit KLK5 and CAMP gene expression and protein secretion in NHEK cells stimulated with calcitriol. Those results were confirmed in 3D models of the skin (RHE and skin ex vivo). The anti-inflammatory effects of ivermectin were associated with an inhibition of IL-8, IL-6 and MCP-1 (CCL2) secretion from NHEK cells. CONCLUSIONS: These results suggest that ivermectin can prevent the inflammatory effects of rosacea triggered by abnormal LL-37 processing, through the inhibition of KLK5 gene expression in the epidermis. Funding: Nestlé Skin Health R&D. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-017-0176-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5453918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-54539182017-06-16 Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models Thibaut de Ménonville, Séverine Rosignoli, Carine Soares, Estelle Roquet, Manon Bertino, Béatrice Chappuis, Jean-Paul Defoin-Platel/Chaussade, Claire Piwnica, David Dermatol Ther (Heidelb) Original Research INTRODUCTION: Numerous intrinsic and extrinsic factors have been associated with the pathophysiology of rosacea, including dysregulation of innate immunity. A high level of cathelicidin antimicrobial peptides (e.g., LL-37) has been shown in the facial skin of patients with rosacea. Excessive production of both LL-37 and KLK5, the serine protease responsible for its cleavage, has been suggested to play a role in the pathophysiology of rosacea. Ivermectin 10 mg/g cream, indicated for the treatment of inflammatory lesions of rosacea, is reported to have dual anti-parasitic and anti-inflammatory properties. However, the exact mechanism of action of ivermectin cream in the treatment of rosacea is unknown. METHODS: This study aimed to evaluate the effect of ivermectin on the expression of KLK5 and the subsequent effect on the maturation process of cathelicidins. Experimental studies were performed either on normal human epidermal keratinocytes (NHEK), reconstructed human epidermis (RHE) or on human skin ex vivo stimulated with calcitriol (1α,25-dihydroxyvitamin D3), which is known to induce KLK5 and LL-37 expression. RESULTS: The results show that ivermectin is able to inhibit KLK5 and CAMP gene expression and protein secretion in NHEK cells stimulated with calcitriol. Those results were confirmed in 3D models of the skin (RHE and skin ex vivo). The anti-inflammatory effects of ivermectin were associated with an inhibition of IL-8, IL-6 and MCP-1 (CCL2) secretion from NHEK cells. CONCLUSIONS: These results suggest that ivermectin can prevent the inflammatory effects of rosacea triggered by abnormal LL-37 processing, through the inhibition of KLK5 gene expression in the epidermis. Funding: Nestlé Skin Health R&D. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-017-0176-3) contains supplementary material, which is available to authorized users. Springer Healthcare 2017-02-27 /pmc/articles/PMC5453918/ /pubmed/28243927 http://dx.doi.org/10.1007/s13555-017-0176-3 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Thibaut de Ménonville, Séverine Rosignoli, Carine Soares, Estelle Roquet, Manon Bertino, Béatrice Chappuis, Jean-Paul Defoin-Platel/Chaussade, Claire Piwnica, David Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models |
title | Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models |
title_full | Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models |
title_fullStr | Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models |
title_full_unstemmed | Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models |
title_short | Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models |
title_sort | topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, ll-37 and klk5, in reconstructed and ex vivo skin models |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453918/ https://www.ncbi.nlm.nih.gov/pubmed/28243927 http://dx.doi.org/10.1007/s13555-017-0176-3 |
work_keys_str_mv | AT thibautdemenonvilleseverine topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels AT rosignolicarine topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels AT soaresestelle topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels AT roquetmanon topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels AT bertinobeatrice topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels AT chappuisjeanpaul topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels AT defoinplatelchaussadeclaire topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels AT piwnicadavid topicaltreatmentofrosaceawithivermectininhibitsgeneexpressionofcathelicidininnateimmunemediatorsll37andklk5inreconstructedandexvivoskinmodels |